Why Is Geron (GERN) Stock Up 94% Today?

Geron (NASDAQ:GERN) stock is rocketing higher on Friday following news that advisors to the Food and Drug Administration (FDA) are backing its blood disorder drug, imetelstat.According to a press release from late-stage clinical biopharmaceutical company, the Oncologic Drugs Advisory Committee (ODAC) voted 12 to two in favor of imetelstat. The ODAC specifically noted that the benefits of the drug outweigh the risks.The ODAC reached its conclusion on imetelstat after reviewing data from a Phase 3 clinical tr ...